Now that September is here, it’s back to business as usual, especially on Wall Street. But something to chew on over the next few days is just how well the biotech sector has done. That sector rallied all last week, which helped to drive the Nasdaq to its first record close since July. The iShares Nasdaq Biotech […]
Innovation, cutting-edge drug technology, clinical expertise, access to capital … all point to repeated FDA approvals, accelerated revenue growth and a winning addition to your portfolio. Here at The Money Street, we have discovered a gem of a Company … a burgeoning biotechnology development company, which has already built a strong AND growing portfolio of […]
